|Table of Contents|

Research molecular typing differences of DCIS,DCIS-MI,DCIS-IDC and IDC

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 01
Page:
60-67
Research Field:
Publishing date:

Info

Title:
Research molecular typing differences of DCIS,DCIS-MI,DCIS-IDC and IDC
Author(s):
ZENG Yihui; HUANG Simin; TANG Dawei; LI Hongen; LI Chengwei; MEI Shiwei
Department of Radiology,Guangdong Province Hospital for Women and Children Healthcare,Guangdong Guangzhou 511400,China.
Keywords:
ductal carcinoma in situ; ductal carcinoma in situ with microinfiltration; invasive ductal cancer; molecular typing
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2025.01.010
Abstract:
Objective:To investigate the differences in molecular staging of ductal carcinoma in situ of the breast(DCIS),ductal carcinoma in situ with microinvasion(DCIS-MI),ductal carcinoma in situ with invasive ductal cancer(DCIS-IDC) and invasive ductal cancer(IDC).Methods:We retrospectively analyzed the data of 2 048 patients with postoperative pathologically confirmed breast cancer in the hospital from January 2012 to November 2022,and recorded the immunohistochemical markers［estrogen receptor(ER),progesterone receptor(PR),human epidermal growth factor receptor-2(Her-2),and markers of proliferative activity of tumor cells(Ki-67)］,molecular typing,and nuclear heterozygosity of the patients in four groups,and compared the differences of immunohistochemical markers,molecular typing,and nuclear heterozygosity among patients of the four groups with the use of the χ2 test or Fisher's exact probability method.Results:2 048 breast cancer patients,of which 181 were in the DCIS group,69 in the DCIS-MI group,702 in the DCIS-IDC group and 1 096 in the IDC group.As for immunohistochemical markers:The differences in the distribution of positivity in ER,PR,Her-2,and Ki-67 among DCIS,DCIS-MI,DCIS-IDC,and IDC patients were all statistically significant(all P＜0.001).The ER- and PR-positive DCIS-MI group were significantly lower than the DCIS group,the DCIS-IDC group,and the IDC group,and the Her-2 positive DCIS-MI group were significantly higher than DCIS group,DCIS-IDC group and IDC group,and Ki-67 high-expression DCIS group were significantly lower than DCIS-MI group,DCIS-IDC group and IDC group,and the differences were all statistically significant(P＜0.001).In terms of molecular typing:Her-2 overexpression type was more common in the DCIS-MI group 55.1%,Luminal B type was predominant in the DCIS-IDC and IDC groups,52.7% and 56.7%,respectively,and the average distribution of Her-2 overexpression type,Luminal A type,and Luminal B type were more common in the DCIS group,32.6%,32.0%,and 31.5%,and there was a statistically significant overall difference in molecular typing among the four groups of data(P＜0.001).The difference was statistically significant when comparing the DCIS,DCIS-MI,DCIS-IDC,and IDC groups two by two(all P＜0.05).In terms of nuclear heterogeneity:The difference in nuclear heterogeneity among DCIS,DCIS-MI and DCIS-IDC patients was statistically significant(P＜0.001).Conclusion:DCIS-MI immunohistochemical markers and molecular typing differ significantly from DCIS,DCIS-IDC,and IDC,and is a different breast cancer component from DCIS.

References:

［1］SIEGEL RL,GIAQUINTO AN,JEMAL A.Cancer statistics,2024［J］.CA Cancer J Clin,2024,74(1):12-49.
［2］PEREZ AA,BALABRAM D,ROCHA RM,et al.Co-expression of p16,Ki67 and COX-2 is associated with Basal phenotype in high-grade ductal carcinoma in situ of the breast［J］.The Journal of Histochemistry and Cytochemistry,2015,63(6):408-416.
［3］VAN SEIJEN M,LIPS EH,THOMPSON AM.Ductal carcinoma in situ:To treat or not to treat,that is the question［J］.The British Journal of Cancer,2019,121(4):285-292.
［4］GIULIANO AE,CONNOLLY JL,EDGE SB,et al.Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual［J］.CA:A Cancer Journal for Clinicians,2017,67(4):290-303.
［5］COWELL CF,WEIGELT B,SAKR RA,et al.Progression from ductal carcinoma in situ to invasive breast cancer:Revisited［J］.Molecular Oncology,2013,7(5):859-869.
［6］SOPIK V,SUN P,NAROD SA.Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ［J］.Breast Cancer Research and Treatment,2018,167(3):787-795.
［7］MA XJ,SALUNGA R,TUGGLE JT,et al.Gene expression profiles of human breast cancer progression［J］.Proceedings of the National Academy of Sciences of the United States of America,2003,100(10):5974-5979.
［8］CHAMPION CD,REN Y,THOMAS SM,et al.DCIS with Microinvasion:Is it in situ or invasive disease［J］.Annals of Surgical Oncology,2019,26(10):3124-3132.
［9］CHIH WAN GOH,吴佳毅,朱丽.乳腺浸润性导管癌伴导管原位癌的病理特征及预后关系研究［J］.外科理论与实践,2019,24(6):550-554. CHIH WAN GOH,WU JY,ZHU L.Study on the pathological features and prognosis of invasive ductal carcinoma of breast with ductal carcinoma in situ［J］.Surgical Theory and Practice,2019,24(6):550-554.
［10］纪涵青,缪姗姗,毛艳,等.乳腺导管原位癌伴微浸润的临床病理特点及远期预后［J］.临床医学进展,2022,12(2):1392-1399. JI HQ,MIAO SS,MAO Y,et al.Clinical and pathological characteristics and long-term prognosis of ductal carcinoma in situ with micro infiltration in the breast［J］.Clinical Medical Progress,2022,12(2):1392-1399.
［11］徐嘉学,王和平,舒皎洁,等.乳腺导管原位癌伴微浸润与导管原位癌的X线与临床病理表现比较分析［J］.浙江创伤外科,2022,27(5):950-952. XU JX,WANG HP,SHU JJ,et al.Comparative analysis of X-ray and clinicopathological features of ductal carcinoma in situ with microinfiltration and ductal carcinoma in situ of breast［J］.Journal of Trauma Surgery,2022,27(5):950-952.
［12］王虎霞，赵静，刘奋德,等.基于SEER数据库分析乳腺分泌性癌与浸润性导管癌的临床病理特征和生存结果［J］.中国医师杂志，2022，24(12):1816-1822. WANG HX,ZHAO J,LIU FD,et al.The clinicopathologic features and survival outcomes of breast secretory carcinoma and invasive ductal carcinoma were analyzed based on SEER database［J］.Chinese Journal of Medical Medicine,2022,24(12):1816-1822.
［13］ GNANT M,THOMSSEN C.St.Gallen 2011:Summary of the consensus discussion［J］.Breast Care,2011,6(2):136-141.
［14］GOLDHIRSCH A,WINER EP,COATES AS,et al.Personalizing the treatment of women with early breast cancer:Highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013［J］.Annals of Oncology,2013,24(9):2206-2223.
［15］ D CRAIG ALLRED,STEWART J ANDERSON,SOONMYUNG PAIK,et al.Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ:A study based on NSABP protocol B-24［J］.Journal of Clinical Oncology,2012,30(12):1268-1273.
［16］RYAN R,TAWFIK O,JENSEN RA,et al.Current approaches to diagnosis and treatment of ductal carcinoma in situ and future directions［J］.Prog Mol Biol Transl Sci,2017,151:33-80.
［17］孙亚冬,李连方,刘山青,等.乳腺导管原位癌与导管原位癌伴微浸润的临床病理特点及预后对比分析［J］.中国实验诊断学,2019,23(5):818-822. SUN YD,LI LF,LIU SQ,et al.Comparative analysis of clinicopathological features and prognosis of ductal carcinoma in situ and ductal carcinoma in situ with microinfiltration［J］.Chinese Journal of Experimental Diagnostics,2019,23(5):818-822.
［18］MARDEKIAN SK,BOMBONATI A,PALAZZO JP.Ductal carcinoma in situ of the breast:The importance of morphologic and molecular interactions［J］.Human Pathology,2016,49:114-123.
［19］PRUNERI G,LAZZERONI M,BAGNARDI V,et al.The prevalence and clinical relevance of tumor-infiltrating lymphocytes(TILs) in ductal carcinoma in situ of the breast［J］.Annals of Oncology,2017,28(2):321-328.
［20］KATHLEEN LAMBEIN,MIEKE VAN BOCKSTAL,LIES VANDEMAELE,et al.Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression［J］.Virchows Archiv,2017,471(5):575-587.
［21］SERRANO-GOMEZ SJ,FEJERMAN L,ZABALETA J.Breast cancer in Latinas:A focus on intrinsic subtypes distribution［J］.Cancer Epidemiology,Biomarkers and Prevention,2018,27(1):3-10.
［22］ZUO T,ZENG H,LI H,et al.The influence of stage at diagnosis and molecular subtype on breast cancer patient survival:A hospital-based multi-center study［J］.Cancer,2017,36(11):647-656.
［23］ LEE SB,SOHN G,KIM J,et al.A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer［J］.Breast Cancer Research and Treatment,2018,169(2):257-266.
［24］钱秀珍,钱永坤.乳腺导管原位癌与浸润性导管癌激素受体及HER-2表达的比较［J］.中华乳腺病杂志(电子版),2013,7(02):97-101. QIAN XZ,QIAN YK.Comparison of hormone receptor and HER-2 expression between ductal carcinoma in situ and invasive ductal carcinoma of the breast［J］.Chinese Journal of Breast Disease(Electronic Edition),2013,7(02):97-101.
［25］张良,孙圣荣,陈创,等.乳腺导管原位癌,微浸润癌及浸润性癌临床病理指标表达差异分析［J］.临床外科杂志,2014,22(12):907-909,913. ZHANG L,SUN SR,CHEN C,et al.Expression difference of clinicopathological indicators in ductal carcinoma in situ,microinvasive carcinoma and invasive carcinoma of breast［J］.Journal of Clinical Surgery,2014,22(12):907-909,913.
［26］WANG L,ZHANG W,LYU S,et al.Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast［J］.Tumour Biology,2015,36(4):2241-2248.
［27］刘仪萱,姚峰.乳腺导管原位癌伴微浸润与浸润癌患者的临床特征对比分析［J］.现代肿瘤医学,2021,29(21):3766-3769. LIU YX,YAO F.Comparative analysis of clinical features of breast ductal carcinoma in situ with microinvasion and invasive carcinoma［J］.Modern Oncology,2021,29(21):3766-3769.
［28］张敏,林青,苏晓慧,等.乳腺导管原位癌伴微浸润与导管原位癌的临床病理及X线表现对比分析［J］.中华放射学杂志,2022,56(2):182-187. ZHANG M,LIN Q,SU XH,et al.Comparison of clinicopathological and X-ray findings between ductal carcinoma in situ with microinfiltration and ductal carcinoma in situ［J］.Chinese Journal of Radiology,2022,56(2):182-187.
［29］PU T,ZHONG X,DENG L,et al.Long term prognosis of ductal carcinoma in situ with microinvasion:A retrospective cohort study［J］.Int J Clin Exp Pathol,2018,11(5):2665-2674.
［30］LIU BT,DING JN,WANG JL,et al.Differences in pathologic characteristics between ductal carcinoma in situ (DCIS),DCIS with microinvasion and DCIS with invasive ductal carcinoma［J］.Int J Clin Exp Pathol,2020,13(5):1066-1072.
［31］郑媛,陈波.浸润性导管癌合并导管原位癌的临床病理特点分析［J］.临床外科杂志,2021,29(11):1047-1049. ZHENG Y,CHEN B.Clinicopathological characteristics of invasive ductal carcinoma complicated with ductal carcinoma in situ［J］.Journal of Clinical Surgery,2021,29(11):1047-1049.
［32］LEE CW,WU HK,LAI HW,et al.Preoperative clinicopathologic factors and breast magnetic resonance imaging features can predict ductal carcinoma in situ with invasive components［J］.Eur J Radiol,2016,85(4):780-789.
［33］FANG Y,WU J,WANG W,et al.Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion［J］.Oncotarget,2016,7(39):64182-64190.
［34］CO M,KWONG A.Ductal carcinoma in situ of the breast -Long term results from a twenty-year cohort［J］.Cancer Treat Res Commun,2018,14:17-20.
［35］聂晨蕾,易春蓓,巩海燕,等.乳腺导管内癌及导管内癌伴微浸润的临床、病理及超声特征对比研究［J］.中国肿瘤外科杂志,2020,12(1):32-36. NIE CL,YI CB,GONG HY,et al.Comparative study of clinical,pathologic and ultrasonic characteristics of intraductal carcinoma of breast and intraductal carcinoma with microinvasion［J］.Chinese Journal of Surgical Oncology,2020,12(1):32-36.
［36］郭瑶,权毅.乳腺导管原位癌发生微浸润的影响因素分析［J］.山东医药,2017,57(24):86-88. GUO Y,QUAN Y.Analysis of influencing factors of microinfiltration in breast ductal carcinoma in situ［J］.Shandong Medicine,2017,57(24):86-88.

Memo

Memo:
-
Last Update: 1900-01-01